RT Journal Article
SR Electronic
T1 Serum Levels of S-100B Protein and Neuron-specific Enolase in Glioma Patients: A Pilot Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2511
OP 2514
VO 24
IS 4
A1 MAAIKE J. VOS
A1 TJEERD J. POSTMA
A1 FRANS MARTENS
A1 BERNARD M.J. UITDEHAAG
A1 MARINES A. BLANKENSTEIN
A1 W. PETER VANDERTOP
A1 BEN J. SLOTMAN
A1 JAN J. HEIMANS
YR 2004
UL http://ar.iiarjournals.org/content/24/4/2511.abstract
AB Background: Serum levels of S-100B protein (S-100B) and neuron-specific enolase (NSE) are elevated after various cerebral injuries and are considered markers of central nervous system damage. In brain tumor patients, literature data on the prognostic value of serum S-100(B) and NSE levels are scarse and conflicting. Patients and Methods: We assessed serum S-100B and NSE levels in 20 consecutive cerebral glioma patients, and evaluated serum levels in relation to survival to determine their prognostic value. Kaplan-Meier survival curves were constructed for patients with “high” (> median value) versus “low” (≤ median value) serum S-100B and NSE levels. Results: A statistically significant shorter survival was found in patients with high serum S-100B levels, whereas a similar classification of patients based on serum NSE levels demonstrated no statistically significant difference in survival between the two groups. Conclusion: These preliminary data suggest that serum S-100B might be a prognostic variable in cerebral glioma patients. Further study is warranted to evaluate whether serum S-100B is an additional, independent prognostic variable. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved